New Study Targets COVID-19 Post-Vaccination Syndrome with Experimental Antibody Therapy

A newly launched research effort could provide insight into COVID-19 Post-Vaccination Syndrome (PVS), a condition affecting individuals who develop ongoing symptoms after receiving COVID-19 vaccines. The SPEAR Study Group, formed by biotech company Invivyd and leading medical researchers, will examine whether monoclonal antibody therapies can address this emerging medical issue by targeting lingering spike proteins in the body.

The group was created following clinical reports suggesting that some individuals with PVS experienced symptom relief after receiving PEMGARDA (pemivibart), a monoclonal antibody currently authorized by the FDA for pre-exposure prevention of COVID-19 in immunocompromised patients. Though not approved for treating PVS or Long COVID, the antibody’s mechanism—binding to the SARS-CoV-2 spike protein—has led researchers to investigate its potential in alleviating symptoms possibly caused by persistent spike protein or viral material. These early reports, while anecdotal and uncontrolled, have motivated structured scientific inquiry into the biology of post-vaccine complications.

Key members of the SPEAR Study Group include Dr. Michael Peluso from the University of California, San Francisco, Dr. Amy Proal of the Polybio Research Foundation, and Dr. David Putrino of the Mount Sinai Health System. Together with Invivyd, they will design and guide controlled clinical trials focused on safety, biology, and preliminary outcomes for patients with persistent post-vaccine symptoms. The trials may also incorporate newer monoclonal antibody candidates such as VYD2311.

PVS shares overlapping symptoms with Long COVID, but its post-vaccine onset has raised different scientific questions about immune system response and residual viral proteins. No treatments are currently approved for either condition. This study may help establish whether monoclonal antibodies can clear these spike proteins and potentially reduce or resolve symptoms in some patients. If successful, the research could support future regulatory pathways for expanded therapeutic use of these antibodies.

Article by multiple contributors, based upon information from Invivyd, Inc. press release dated July 2, 2025.

Video Spotlight